ASCO-GI 2021: Agios will file for a new Tibsovo label in 2L cholangiocarcinoma despite an OS advantage setback
Agios Pharmaceuticals presented mature data from its pivotal Phase III study ClarIDHy in cholangiocarcinoma for its IDH1 inhibitor Tibsovo (ivosidenib)…